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Abstract
Passage of the prototypic arenavirus lymphocytic choriomenigitis virus (LCMV) in cultured cells in the presence of the mutagenic agent
5-fluorouracil (FU) resulted in efficient and systematic virus extinction under conditions that did not significantly affect cell survival.
FU-mediated extinction of LCMV was associated with 3.6- to 10-fold increases in the mutation frequencies for the three viral genes
examined, but with only very modest effects on virus replication and transcription during a single round of infection. Likewise, FU did not
affect expression of a LCMV minigenome. In contrast, the well documented antiviral effect of ribavirin against LCMV was not associated
with significant increases in virus mutation frequencies, but rather with a dramatic inhibition of both viral RNA synthesis and LCMV
minigenome expression. Mutagen induced viral extinction has been recently reported for positive strand RNA viruses polio and foot-and-
mouth disease, and the lentivirus HIV-1. Our findings indicate that lethal mutagenesis can be effective also against LCMV, a negative strand
RNA virus. Moreover, FU treatment prevented the establishment of LCMV persistent infection in mice deficient in B and T cells, suggesting
the feasibility in vivo of lethal mutagenesis as a novel antiviral strategy.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Riboviruses usually exhibit extensive genetic variability
and potential for rapid evolution (Holland et al., 1982;
Holland, 1992; Domingo et al., 2001). The molecular basis
for this variation is extremely high mutation frequencies per
average site in RNA virus genomes (Drake and Holland,
1999). This in turn is facilitated by the error-prone nature of
the RNA-dependent RNA polymerases (RdRp), enzymes
for which efficient proofreading activity has not been yet
demonstrated (Steinhauer et al., 1992). Such high mutation
frequencies, combined with small genome sizes, short rep-
lication cycles and high fecundity, dictate that RNA viruses
replicate and evolve as dynamic complex mutant distribu-
tions termed quasispecies (Eigen and Biebricher, 1988).
Error-prone replication predicts that for a given genomic
complexity there is a critical copying fidelity below which
information can no longer be maintained. Any further de-
crease in fidelity would result in the so-called error catas-
trophe (Swetina and Schuster, 1982; Schuster and Stadler,
1999), which is accompanied by total loss of information
associated with the RNA genome sequence and thereby
virus extinction. Studies on the effect of chemical mutagen-
esis on mutation frequencies of poliovirus (PV) and vesic-
ular stomatitis virus (VSV) showed that mutation frequen-
cies at defined single-nucleotide sites could be increased
only very modestly (1.1- to 2.8-fold) even with losses in
virus survival higher than 99% (Holland et al., 1990). These
results, together with the generally observed high mutation
rates during RNA genome replication (Drake and Holland,
1999), provide strong support for the view that riboviruses
replicate very near the threshold for error catastrophe. Near
the error threshold virus viability is maintained for a sub-
stantial percentage of progeny, while generation of an enor-
mous spectrum of mutants is ensured, thus facilitating virus
adaptation. The composition of these quasispecies is deter-
mined by competitive fitness under prevailing conditions
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(Eigen and Biebricher, 1988). This allows riboviruses to
maintain themselves stably in a given ecological niche,
while retaining the ability to adapt quickly to changing
conditions.
The genetic structure of quasispecies intrinsic to ribovi-
ruses can impact anti-viral therapies significantly. Thus,
even before exposure to a drug, the ensemble of related
genome species within the viral quasispecies may already
contain drug-resistant variants, or mutants that are one mu-
tation away from becoming drug resistant. This situation
also applies to the use of antiviral immune molecules and
cells, as illustrated by the frequent emergence of variants
resistant to neutralizing antibodies and cytotoxic T cells. On
the other hand, proximity to error catastrophe during ribo-
virus replication raises the intriguing possibility of using
mutagenic agents to drive RNA viruses into error catastro-
phe, thus causing virus extinction. Recent findings with the
picornaviruses foot-and-mouth disease (Sierra et al., 2000;
Pariente et al., 2001) and poliovirus (Crotty et al., 2000;
Crotty et al., 2001), as well as with the flavivirus GB virus
(Lanford et al., 2001) and the lentivirus HIV-1 (Loeb et al.,
1999), have provided strong support for the feasibility of
this novel antiviral approach which has been referred to as
lethal mutagenesis (Loeb et al., 1999).
In this paper we examine whether an antiviral strategy
based on the concept of lethal mutagenesis can also be
efficiently used against the prototypic arenavirus lympho-
cytic choriomeningitis virus (LCMV). Arenaviruses merit
significant attention both as experimental models to study
virus-host interactions (Buchmeier and Zajac, 1999) and as
clinically important human pathogens, including hemor-
rhagic fever agents such as Lassa virus (Peters et al., 1996;
McCormick and Fisher-Hoch, 2002; Peters, 2002). LCMV
is an enveloped virus with a bisegmented negative strand
RNA genome. Its molecular biology has been recently re-
viewed (Salvato, 1993; Southern, 1996; Meyer et al., 2002).
The two genomic RNA segments are designated L and S,
and have approximate sizes of 7.2 and 3.4 kb, respectively.
The S RNA directs synthesis of the nucleoprotein, NP (ca
63 kDa), and the two virion glycoproteins, GP-1 and GP-2,
that are derived by posttranslational cleavage of a precursor
polypeptide, GP-C. GP-1 and GP-2 make up the spikes on
the virion envelope, and mediate virus interaction with the
host cell surface receptor (Cao et al., 1998; Kunz et al.,
2002). The L RNA segment codes for the virus RNA-
dependent RNA polymerase (RdRp) (L, ca 200 kDa) (Sal-
vato et al., 1989) and a small (11 kDa) RING finger protein
called Z (Salvato and Shimomaye, 1989; Salvato et al.,
1992) whose roles in the virus life cycle are poorly under-
stood (Salvato et al., 1992; Campbell Dwyer et al., 2000;
Cornu and de la Torre, 2001; Djavani et al., 2001; Kentsis
et al., 2001). The NP and viral polymerase are complexed
with the genomic viral RNA to form ribonucleoprotein
(RNP) complexes, which are active in virus transcription
and replication (Fuller-Pace and Southern, 1989; Cornu and
de la Torre, 2001).
We show that serial LCMV passages in the presence of
the mutagenic agent 5-fluorouracil (FU), at a concentration
compatible with good cell survival (80%), resulted in
efficient and systematic virus extinction. FU-mediated ex-
tinction of LCMV was associated with increases in the
mutation frequencies for the three viral genes examined: NP
(3.6-fold), GP (10.0-fold), and L-polymerase (5.9-fold). The
concentration of FU (200 g/ml) used to cause LCMV
extinction caused only modest decreases in virus replication
and transcription during a single round of infection, and did
not affect expression of a LCMV minigenome. In contrast,
and contrary to the findings described for PV, the antiviral
activity of ribavirin (Rib) against LCMV was not associated
with significant increases in the mutation frequencies of the
same LCMV genes, but rather with a dramatic inhibition of
both viral RNA synthesis and LCMV minigenome expres-
sion. We also show that FU treatment prevented the estab-
lishment of LCMV persistent infection in mice deficient in
B and T cells (RAG2/) (Alt et al., 1992; Shinkai et al.,
1993), suggesting the feasibility in vivo of lethal mutagen-
esis as a novel antiviral strategy.
Results
Effect of FU and Rib on LCMV multiplication during a
single round of infection
We first examined the effect of increasing amounts of FU
and Rib on the viability of BHK21 cells (Fig. 1). For this,
we treated BHK-21 cells with increasing concentrations of
FU or Rib, and at the indicated post-exposure times cell
viability was determined by staining with the supravital dye
neutral red and exclusion of the dye trypan blue. Cells
treated with FU concentrations of 50 or 200 g/ml exhibited
more than 90 and 80%, respectively, viability after 48 h
treatment. Increasing the concentration of FU to 800 g/l
resulted in significant levels (more than 30%) of cell death.
Consistent with a previously reported low cell toxicity of
Rib (Huggins et al., 1984), all the Rib concentrations we
tested had only minimal effects on cell survival after 48 h
treatment (Fig. 1).
We then assessed the effect of the presence of increasing
amounts of FU or Rib during a single-step LCMV growth.
BHK-21 cells were treated with the indicated concentrations
of FU or Rib and subsequently infected with LCMV ARM
(MOL of 3). At indicated times, titers of infectious virus in
the culture cell media were determined by plaque assay.
Increasing concentrations of FU and Rib correlated with
decreases in virus production (Fig. 2). For the same set of
samples we also determined levels of virus replication and
transcription at 24 h p.i. For this, total cellular RNA was
isolated and analyzed by Northern blot using a LCMV-NP
probe to detect genome S RNA (replication) and NP mRNA
(transcription). Hybridization signals were quantified by
PhosphorImager and normalized with respect to those found
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in untreated cells (defined as 100%). As with virus titers,
levels of LCMV replication and transcription were increas-
ingly reduced with increases in drug concentrations (Fig. 3).
At the concentrations tested, Rib had a more severe effect
than FU on viral RNA synthesis. Thus, we could detect
LCMV replication and transcription at the highest (800
g/ml) FU dose used, whereas in cells treated with 200 or
400 M Rib levels of LCMV replication and transcription
were below the sensitivity of our Northern blot assay.
The reduction of about 100-fold in virus production in
cells treated with 200 g/ml of FU was associated with
about a five-fold reduction in RNA synthesis. In contrast, a
similar reduction in virus production in cells treated with
200 M Rib was accompanied by undetectable levels of
viral RNA synthesis (compare Figs. 2 and 3). This finding
suggested that FU and Rib were likely exerting their anti-
viral actions against LCMV via different mechanisms. Con-
sistent with this view, FU and Rib differed also in their
ability to inhibit the expression of a LCMV minigenome
(MG) mediated by plasmid-supplied viral transacting fac-
tors (Fig. 4). At the drug concentrations that caused a
100-fold reduction in virus production, FU caused only a
10% inhibition of LCMV MG expression, whereas Rib
completely abrogated MG expression. Western Blot analy-
sis showed that expression levels of plasmid supplied
LCMV trans-acting factors NP and L proteins were similar
in FU (200 g/ml) and Rib (200 M) treated cells, and only
Fig. 1. BHK-21 cell viability in the presence of FU and Rib. BHK-21 cells were seeded (1  105 cells/well) on M6-well plates. Twelve h later, cells were
treated with the indicated concentrations of FU or Rib. At the indicated times after drug exposure, numbers of viable cells were determined as described in
Material and Methods. Percent cell viabilities were normalized with respect to the corresponding untreated control cells. Values represent the average (SD)
of two independent experiments, with each time point done in triplicate.
Fig. 2. Effect of FU and Rib on LCMV ARM multiplication during one
single round of infection. BHK-21 cells were treated for six h with the
indicated concentrations of FU or Rib, and then infected with LCMV
(m.o.i. of 2 PFU/cell). At the indicated post-infection (p.i.) times, super-
natants were collected and titrated for infectious LCMV by plaque assay on
Vero cells as detailed in Materials and Methods. Each time p.i. value
represents the average of two independent experiments. Standard devia-
tions (not included) never exceeded 10%.
Fig. 3. Effect of FU and Rib on LCMV RNA synthesis. After six h of drug
exposure, BHK-21 cells were infected with LCMV ARM (m.o.i. of 2
PFU/cell). At the indicated p.i. times, total cellular RNA was isolated and
analyzed by Northern blot as described in Materials and Methods. Hybrid-
ization signals of the S genomic RNA and NP mRNA sepecies in drug-
treated cells were normalized with respect to the corresponding signals in
untreated control cells.
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slightly reduced compared to those seen in drug-untreated
control samples (data not shown).
Effect of FU and Rib on serial passages of LCMV
For these studies we used FU and Rib at concentrations
of 200 g/ml and 400 M, respectively. These drug con-
centrations were selected based on their effects on cell
survival (Fig. 1) and LCMV multiplication during one-step
growth (Figs. 2 and 3). Drug effects on LCMV multiplica-
tion were monitored by determining virus titers in the su-
pernatant of each serial passage and intracellular levels of
virus RNA. Production of infectious virus was not detected
after the first and second serial passage in the presence of
Rib or FU, respectively (Fig. 5A). Likewise, after the sec-
ond (Rib) and third (FU) passage in the presence of drugs,
intracellular LCMV RNA was undetectable by RT-PCR,
(Fig. 5B). These findings were consistent with a well doc-
umented antiviral activity of Rib against arenaviruses, and
raised the possibility that treatment with FU could also
cause systematic extinction of LCMV under our cell culture
conditions. To test this hypothesis, we did ten independent
replicas of serial passages of LCMV in the absence or
presence of FU (200 g/ml); the results were similar among
the ten independent replicas (Fig. 6A, B). In the absence of
FU, both infectious virus and viral RNA were readily de-
tected and virus titers and viral RNA did not vary signifi-
cantly among passages. In contrast, in the presence of FU
infectious virus was not detected after the second passage,
and after the third passage intracellular LCMV RNA was
undetectable by RT-PCR. Removal of FU after the third
passage and subsequent passages in the absence of drug did
not allow recovery of infectious virus in the supernatant
(Fig. 6A) or detection of intracellular viral RNA (Fig. 6C).
Moreover, inoculation (i.v.) of IFNa/bR-KO mice (N  5)
with 0.5 ml of the supernatant of FU-P3 did not result in a
productive infection, whereas all IFNa/bR-KO mice (N 
5) inoculated with 0.5 ml of medium containing 1 PFU of
LCMV ARM developed viremia (range 7  105 to 2  106
PFU/ml in serum) (data not shown). This assay was done
based on our observation that IFNa/bR-KO mice provide us
with a readout for infectious LCMV that is about 100-fold
more sensitive than the standard plaque assay on Vero cells.
Effect of FU and Rib on LCMV mutation frequencies
The mutagenic action of FU on riboviruses is well doc-
umented (Pringle, 1970; Holland et al., 1990; Sierra et al.,
Fig. 5. Serial passages of LCMV ARM in the presence of FU (200 g/ml)
or Rib (400 M). Supernatants of each indicated passage in the presence
of FU or Rib as well as untreated control cells were assayed for infectious
LCMV by plaque assay (A). Total cellular RNA was isolated from the
indicated passages in the presence of FU (B), or Rib (C), and analyzed by
RT–PCR. The RT reaction was primed with random hexamers and the
resulting cDNAs were amplified with specific primers for the virus NP or
the cellular housekeeping gene GAPDH.
Fig. 4. Effect of FU and Rib on LCMV MG expression. BHK-21 cells
treated with the indicated amounts of FU or Rib and untreated control cells
were infected with vTF7.3 and subsequently transfected with the plasmid
expressing the LCMV MG and support plasmids expressing the minimal
viral trans-acting factors NP and L as described in Materials and Methods.
At 24 h post-transfection, cell lysates were prepared for CAT assay. Equal
amounts of protein from each lysate were used for the CAT assay. Amount
of cell extract and reaction time were adjusted to provide linear conditions
of enzyme activity (less than 40 % of Cm conversion). CAT activity in
each sample was normalized with respect to that associated with lysates of
drug-untreated cells (100%). Shown are the average of three independent
experiments. Standard deviations (not shown) never exceeded 5%.
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2000; Pariente et al., 2001), and more recent studies with
PV have shown that Rib also can have a mutagenic activity
(Crotty et al., 2001). Evidence indicates that the mutagenic
action of both FU and Rib are responsible for dramatic
losses in the virus infectivity upon treatment with these
drugs, a process that has been called lethal mutagenesis
(Loeb et al., 1999). We therefore examined whether lethal
mutagenesis was also at the root of FU- and Rib-mediated
elimination of LCMV in cultured cells. With this aim we
determined the mutation frequency values in preextinction
viral populations (FU-P2 and Rib-P1), and compared these
values with those of an untreated control virus population
(P5) (Table 1).
We used RT-PCR procedures to amplify LCMV
genomic regions of the NP, GP and L viral genes. The size
of the region amplified for each of the three genes was
similar (ca. 500 bp). For each sample and gene region we
sequenced a similar number of clones derived from three
independent RT-PCR reactions. This approach was fol-
lowed to minimized bias due to the possible amplification of
mutations introduced by the RT-PCR procedure. To deter-
mine the mutation frequencies in the NP, GP and L regions
analyzed, we counted only once each different mutation
found within each virus population examined.
The untreated control P5 virus population exhibited mu-
tation frequencies in the range of 2.6  104 to 5.5  104
mutations per nucleotide, compared to the parental LCMV
ARM used for these studies. These values are consistent
with previous findings about genetic heterogeneity of
LCMV (Sevilla et al., 2002), and other arenaviruses (Bowen
et al., 1997; Bowen et al., 2000; Sevilla et al., 2002), and
also within the range commonly observed for riboviruses
(Domingo et al., 2001). Compared to untreated control P5,
the Rib-P1 preextinction LCMV population did not exhibit
significant increases in mutation frequencies for any of the
three genomic regions examined. In contrast, the FU-P2
preextinction population had increases in mutation frequen-
cies ranging from 3.6 (NP gene) to 10.0 (GP gene). More-
over, for the three genomic regions analyzed, FU-P2 had
increased Shannon entropies (Table 1), which is a measure
of the different molecular species present within the mutant
spectrum of the population (Volkenstein, 1994). Thus, the
complexity of the mutant spectrum was increased in FU-P2
compared to Rib-1 and P5 populations. Among the 49
different nucleotide substitutions found in FU-P2, the two
more abundant were transitions A to G (18/49, 36.7%) and
U to C (16/49, 32.6%) (Table 2), which have been associ-
ated with the mutagenic action of FU (Yu et al., 1993). We
observed a nonuniform distribution of mutations accross the
LCMV genome regions examined. Thus, GP exhibited 1.7
and 2.8 higher increases in mutation frequencies than L and
NP, respectively, but the three genomic regions examined in
FU-P2 had a similar distribution of synonymous vs non-
synonymous mutations. Synonymous substitutions repre-
sented 23.8% (5/16), 21.4% (3/11) and 28.5% (4/10) of the
mutations found in GP, NP and L, respectively. These
frequencies of synonymous substitutions are comparable to
what would be expected on a random basis (ca. 21%).
Effect of FU on LCMV infection of RAG2/ mice
The high efficiency with which FU mediated extinction
of LCMV in cultured cells led us to investigate whether
FU-induced lethal mutagenesis could be observed during
LCMV infection of its natural host the mouse. In the adult
immunocompetent mouse LCMV infection is controlled by
a vigorous T-cell response that eventually results in viral
clearance from blood and tissues. This host immune re-
sponse would be a confounding factor when trying to assess
Fig. 6. Systematic and rapid extinction of LCMV by FU treatment. Shown
are three representative cases of ten independent replicas of LCMV serial
passages in the presence of FU (200 g/ml) done as described Fig. 5.
LCMV titers were determined in supernatants of each passage (A). Like-
wise, for each passage the presence of intracellular LCMV RNA was
determined by RT-PCR using specific primers to amplify a segment of the
NP gene (about 500 bp), and as a control a segment (about 200 bp) of the
cellular housekeeping GAPDH gene (B). In a set (five) of additional
replicas of serial passages, FU was removed at P3 and subsequent passages
(P4 to P7) were done in the absence of drug. Virus titers in supernatants of
P4 to P7 (A, dotted lines), and intracellular LCMV RNA in P6 and P7 (C)
of two of the five replicas were determined as described in sections A and
B of this figure.
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the direct effect of FU on LCMV multiplication. To over-
come this limitation we used RAG2-KO mice, which lack
mature T and B cells due to a deletion of recombination
activating gene-2 (Alt et al., 1992; Shinkai et al., 1993).
LCMV infection of these genetically altered mice results in
the establishment of a persistent infection where infectious
virus can be readily detected in blood and tissues for long
periods of time.
We infected RAG2-KO mice with LCMV ARM (100
PFU/mouse, i.p.) and treated them either with FU or PBS
Table 1
LCMV genetic heterogeneity in control and pre-extinction populations
Gene Mutagen Clonesa Nucleotidesb Mutationsc
N (%)
Mutationd
frequency
(104)
Increasede
mutation
frequency
Normalizedf
Shannon
entropies
NP None 11 5473 3 (42.8) 5.5 — 0.37
Fu 14 7142 14 (28.6) 19.6 3.6 0.85
Rib 10 5280 3 (30.0) 5.4 1.0 0.35
GP None 15 7529 2 (28.6) 2.6 — 0.18
Fu 16 7911 21 (42.8) 26.5 10.2 0.76
Rib 12 6120 2 (25.0) 3.3 1.3 0.20
L None 12 6394 2 (28.6) 3.1 — 0.23
Fu 14 7583 14 (28.6) 18.5 6.0 0.78
Rib 12 6720 3 (30.0) 4.5 1.5 0.25
Overall None — 19396 7 — 3.6 — —
Fu — 22636 49 — 21.6 6.0 —
Rib — 21545 8 — 4.1 1.1 —
Note. RNA was isolated from the last serial passage in the presence of FU (FU-P2), or Rib (Rib- P1), where viral RNA could be still detected by RT-PCR.
RNA from untreated control population was from P5. RNA samples were subjected to RT-PCR and the corresponding products cloned in E. coli following
procedures described in Materials and Methods.
a Number of independent cDNA clones in E.coli that were analyzed for each virus genomic region examinied.
b Total number of nucleotides sequenced for each virus genomic region.
c Number of mutations (N) found in each genomic region analyzed (NP, GP and L) and its percent with respect to the total number of mutations found
in the the three genomic regions of the corresponding population.
d Determined by comparing sequences determined after serial passages under indicated conditions with that of the parental ARM reference sequence that
was not subjected to serial passages.
e Determined with respect to the untreated control population.
f The normalized Shannon entropy was calculated as - (pi  lnpi)/lnN in which pi is the frequency of each sequence in the quasispecies and N is the total
number of sequences compared.
Table 2
Types of mutations in the mutant spectrum of LCMV aRMS control (CNT-P5) and pre-extinction (FU-P2 and Rib-P1) populations
CNT-P5 FU-P2 Rib-P1
GP NP L GP NP L GP NP L
A3C 0 0 0 0 0 0 0 0 0
A3G 1 0 0 10 3 5 1 0 1
A3U 0 0 0 1 1 0 0 0 0
C3A 0 0 0 0 0 0 0 0 0
C3G 0 0 0 0 0 0 0 0 0
C3U 0 0 1 3 3 1 0 1 1
G3A 0 1 0 3 0 2 1 1 0
G3C 1 0 0 0 0 0 0 0 0
G3U 0 0 0 0 0 0 0 0 0
U3A 0 0 0 0 1 0 0 0 0
U3C 0 1 1 4 6 6 0 1 1
U3G 0 1 0 0 0 0 0 0 0
Deletions 0 0 0 0 0 0 0 0 0
Total 2 3 2 21 14 14 2 3 3
Transitions 1 2 2 20 12 14 2 3 3
Transversions 1 1 0 1 2 0 0 0 0
Synonymous 1 2 0 5 3 4 1 2 1
Non-synonymous 1 1 2 16 11 10 1 1 2
Note. Mutations were determined by comparison of serially passaged populations with the parental ARM reference sequence.
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following the protocol described in Materials and Methods.
At 12 days p.i. serum and spleen tissue were collected and
analyzed for virus titers and presence of viral RNA by
RT-PCR. The four mice treated with PBS had high titers of
LCMV in serum and spleen, whereas 3 out of 4 mice treated
with FU did not have detectable levels of infectious virus in
serum or spleen (Fig. 7). The remaining FU-treated mouse
had significant decreased virus titers in serum and spleen
compared to PBS-treated control mice. Consistent with re-
sults of virus titers, RNA was detected in the spleen of the
four mice treated with PBS, whereas among the FU-treated
mice only the one positive for infectious virus was also
positive for RNA in spleen. Thus, treatment of RAG/
mice with FU was effective in preventing the establishment
of a persistent infection with LCMV.
Discussion
Initial studies on the effect of chemical mutagenesis on
mutation frequencies and viability of PV and VSV showed
that mutation frequencies at defined single-nucleotide sites
could be increased only very modestly (1.1- to 2.8-fold)
even with losses in virus survival higher than 99% (Holland
et al., 1990). These results provided the first direct experi-
mental evidence that riboviruses may replicate very near the
threshold for error catastrophe, a critical error rate, pre-
dicted from theoretical studies, to set a limit for mainte-
nance of genetic information (Swetina and Schuster, 1982;
Eigen and Biebricher, 1988; Eigen, 2000). More recent
studies with HIV-1 (Loeb et al., 1999), the picornaviruses
FMDV (Sierra et al., 2000; Pariente et al., 2001), and PV
(Crotty et al., 2000; Crotty et al., 2001), as well as GB virus
B (Lanford et al., 2001), have shown the feasibility of using
mutagens as antiviral drugs against riboviruses. In the case
of FMDV and HIV-1, treatment with mutagens led to virus
extinction, which has been called lethal mutagenesis (Loeb
et al., 1999; Sierra et al., 2000). The use of this strategy to
combat riboviruses in general would require its efficacy also
against negative strand RNA viruses, whose basic replica-
tion strategy differs significantly from that of positive strand
riboviruses and lentiviruses. Our results show that lethal
mutagenesis is also effective in causing systematic extinc-
tion in cultured cells of LCMV, a negative strand RNA
virus. Moreover, our findings also suggest that this novel
antiviral approach may be feasible in vivo.
Consistent with previous reports (McKee et al., 1988;
Huggins, 1989; de la Torre and Oldstone, 1992), Rib (200
M) had a powerful inhibitory effect on LCMV multipli-
cation. Recent studies with PV have led to the intriguing
proposal that the antiviral activity of Rib is related to its
mutagenic action on genome RNA during replication me-
diated by the virus RdRp (Crotty et al., 2000; Crotty et al.,
2001). This hypothesis would predict that Rib-mediated
elimination of LCMV occurs also via lethal mutagenesis.
However, our data show that the inhibitory effect of Rib on
LCMV multiplication was not associated with a significant
increase in mutation frequencies in the virus genome (Table
1), but rather with the abrogation of RNA synthesis medi-
ated by the LCMV polymerase (Figs 2, 3, and 4). A number
of different mechanisms have been proposed to account for
the antiviral activity of Rib (Snell, 2001). It is plausible that
the prominent mechanism of action of Rib may vary for
different types of viruses, and that while for PV its main
antiviral effect is through enhanced mutagenesis, other
mechanisms operate in the case of LCMV. Also, the isola-
tion of Sindbis virus variants resistant to Rib (Scheidel et
al., 1987; Scheidel and Stollar, 1991) suggests that lethal
mutagenesis is unlikely to be the antiviral mechanism of Rib
against this alphavirus.
FU is incorporated into RNA and has been shown to be
mutagenic for a number of RNA viruses (Pringle, 1970;
Holland et al., 1990; Sierra et al., 2000; Pariente et al.,
2001). In addition, low concentrations (1 g/ml) of FU has
been shown to have a potent inhibitory effect on the repli-
cation of rinderpest virus (Ghosh et al., 1996). Moreover,
FU can also interfere with RNA processing and translation
(Parker and Cheng, 1990), which could affect expression of
host cell factors required for virus multiplication. However,
our results (Figs. 2 and 3) indicate that such effects, though
they likely contribute, cannot account for the observed FU-
mediated extinction of LCMV. Our findings rather point to
FU-enhanced mutagenesis of LCMV genome as the driving
force of LCMV extinction (Table 1). Consistent with the
mutagenic action of FU (Parker and Cheng, 1990; Yu et al.,
1993), transitions (A to G and U to C) were the most
abundant mutations found in FU-P2 preextinction popula-
tion (Table 2). We observed a nonuniform distribution of
mutations across the three LCMV genome regions exam-
ined, suggesting that results based on the examination of
only one genomic region could be misleading. However, the
three genomic regions had a similar distribution of synon-
Fig. 7. Effect of FU treatment on LCMV infection of RAG2 KO mice.
Treatment with FU and LCMV infection of RAG2 KO mice were done as
detailed in Material and Methods. Twelve days p.i., serum and spleen
tissue were collected from FU (N  4) and PBS (N  4) treated mice, and
assayed for infectious LCMV by plaque assay.
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ymous vs non-synonymous mutations (Table 2). We cannot
rule out that one particular mutation could be the result of
misincorporation during the RT-PCR amplification instead
of spontaneous or mutagen induced. Nevertheless, control
experiments have shown that under the experimental con-
ditions we used for RT-PCR, the vast majority of the mu-
tations detected corresponded to those present in the virus
RNA (Najera et al., 1995; Sauder et al., 1996).
Studies with FMDV have shown that low viral loads and
low relative fitness favor viral extinction (Pariente et al.,
2001). Efficient extinction of FMDV required the combina-
tion of the mutagen FU with an antiviral drug (Pariente et
al., 2001). In contrast, FU alone was highly efficient in
mediating rapid extinction of LCMV. At the present time
we can only speculate about possible reasons for these
differences. Features intrinsic to the replication machineries
of FMDV and LCMV, or in general between positive and
negative strand RNA viruses, could have contributed to
these differences. Thus, for example, recombination is a
very prevalent phenomenon among positive RNA-viruses
and has been implicated in counteracting potentially delet-
erous mutations generated during error prone replication of
riboviruses (Chao, 1990; Domingo and Holland, 1997). In
contrast, homologous recombination is an extremely rare
event during replication of negative strand RNA viruses
(Pringle and Parry, 1982). As with other RdRp, the LCMV
polymerase is likely to carry on several enzymatic processes
associated with different functional domains, which can
contribute to making L highly sensitive to mutational inac-
tivation. The coding region of the LCMV RdRp represents
more than 50% of the virus genome. Assuming a random
distribution of mutations due to FU incorporation into the
nascent chain during RNA replication, the sequence of the
RdRp would be a main target of drug-induced mutagenesis.
This can result in the rapid accumulation of defective poly-
merases with the consequent effect on virus viability. This
can be further enhanced by the specific mutagenic activity
of the drug used. For example within motif C of the LCMV
L polymerase 21 out of 33 nucleotide positions are suscep-
tible to FU-induced transitions during one single round of
replication, with 17 of these 21 nucleotide substitutions
resulting in predicted amino acid changes. Studies using
reverse genetic approaches have shown that the majority of
amino acid substitutions, including conservative ones,
within motifs A and C result in a severely impaired, or
totally inactive, LCMV polymerases. Similar considerations
can be extended to other functional domains within the
LCMV polymerase, which underscores how modest in-
creases in mutation frequencies can have a dramatic impact
on the virus biology.
The quasispecies model of RNA virus population pre-
dicts that entry into error catastrophe would be accompanied
by a randomization of the virus genome sequence, which
should be reflected by the accumulation of hyper-
mutagenized RNA virus genomes. However, we did not
detect hypermutagenized sequences among those derived
from preextinction populations. This apparent discrepancy
can be explained by considering that the prediction of the
quasispecies model is based on the assumption that mutants
generated during decreased copying fidelity of the system
will have similar fitness. In contrast, in the context of the
virus biology many of the mutations introduced into the
replicating virus can result in non-viable genome sequences
without the capability for amplification, and hence unde-
tectable by current biochemical methods. In addition, mu-
tations affecting primer binding sites used for RT-PCR can
prevent amplification of a complete representation of mu-
tant RNA molecules generated during drug-enhanced mu-
tagenesis.
Results from different laboratories using different viral
systems, including those presented here have provided
strong support for using lethal mutagenesis as a novel an-
tiviral strategy against riboviruses. These findings have
raised the pressing question of whether this approach has
some feasibility in vivo. FU treatment of RAG2/ mice
prevented the establishment of a LCMV persistent infec-
tion. The lack of T- and B-cell responses in these mice
suggests a direct effect of FU on virus viability as the reason
for preventing LCMV persistence. Certainly, LCMV infec-
tion of RAG2/ mice is an experimental model that does
not recreate the complex spectrum of host-ribovirus inter-
actions, but our findings provide a first and necessary step to
encourage future research aimed at exploring the potential
of lethal mutagenesis to combat ribovirus infections and
associated diseases. This approach will face a formidable
challenge related to potential toxicity and undesirable clin-
ical side effects associated with this therapy. However,
considering the fast pace at which the field of nucleoside
chemistry is progressing, it seems feasible in the near future
to develop mutagenic nucleoside analogs that can be readily
and specifically incorporated by the viral RdRp but with no
or limited cell toxicity.
Materials and methods
Cells, viruses and infections
Baby hamster kidney cells (BHK-21) were grown in
Dulbecco’s modified minimal essential medium (DMEM)
supplemented with heat inactivated (55°C for 30 min) 10%
fetal calf serum (FCS), 2 mM L-glutamine, 1X tryptose
phosphate broth (TPB), 1 mM sodium pyruvate and 0.5%
glucose. Infections with lymphocytic choriomeningitis virus
(LCMV) were done using a plaque-isolated clonal virus
population of strain Armstrong (ARM). Procedures for in-
fection of BHK-21 cells with LCMV in liquid medium and
for virus titration in Vero cells using semisolid agar medium
have been described (Teng et al., 1996).
Knockout mice lacking the recombination activating
gene-2 (RAG2-KO) (Alt et al., 1992; Shinkai et al., 1993) or
the IFN a/b receptor (IFNa/bR-KO) (Muller et al., 1994),
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were maintained in conditions consistent with the facility
animal care regulation (AAALAC) throughout the course of
investigation. All the studies were done with adult mice
(6–9 weeks old).
Mutagenic agents and mutagenic treatments
FU (Sigma) and Rib (gift from R. Robins) were dis-
solved in DMEM to yield stock solutions of 2.5 mg/ml and
10 mM, respectively. These solutions were sterilized by
filtration (0.22 m membrane filter, Costar). Stock solutions
were aliquoted, stored at 20°C and diluted as needed.
RAG2/ mice (males with average weight 22.5 g, range
22–24) were treated with 2 mg/Kg/day of FU given intra-
peritoneally (i.p.). This treatment follows a dosing regimen
that simulated a chemotherapy protocol used for treatment
of colon cancer (Lucchinetti et al., 1997). Control mice were
inoculated daily also i.p. with the same volume of the drug
diluent, phosphate buffer saline (PBS). Mice were moni-
tored for loss of weight daily. Under the experimental con-
ditions used, FU-treated mice had less than 5% weight loss
compared to PBS-treated control mice.
Analysis of LCMV RNA replication and transcription in
infected cells
To determine levels of LCMV RNA during a single
round of infection in the presence of FU or Rib, drug-treated
and untreated control BHK-21 cells were infected with
LCMV ARM5 at an MOL of 2. At 24 h p.i., RNA was
isolated by using TRIreagent (Molecular Research Center
Inc.) according to the supplier’s protocol and equal amounts
(5 g) analyzed by Northern blot hybridization as described
using a 32P-labeled double strand DNA NP probe (Teng et
al., 1996; Cornu and de la Torre, 2001). This probe detects
both the S genomic RNA (replication) and the NP mRNA
(transcription). Hybridization signals were quantified by
phosphorimager. Intracellular levels of LCMV RNA in se-
rial passages in the presence of FU or Rib were determined
by RT-PCR. The RT reaction was primed with random
hexamers and the resulting cDNAs were amplified by PCR
using specific primers for the virus NP or for the cellular
housekeeping gene GAPDH.
Analysis of LCMV minigenome expression
The analysis of LCMV minigenome expression was
done essentially as described (Lee et al., 2000). Briefly,
BHK-21 cells treated with FU or Rib and untreated control
cells were infected with vTF7.3 at an MOL of 3, and
transfected with pLCMVSCAT2 (MG) (0.5 g), pCITE-NP
(1.5 g), pGEM-L (0.1 g), and pTMI-GFP (0.1 g).
Plasmid pLCMVSCAT2 directs intracellular T7-mediated
synthesis of the LCMVSCAT2 minigenome in which the
viral NP and GP ORF encoded by the S RNA have been
replaced by an antisense (AS) copy of the chloramphenicol
acetyltransferase (CAT) ORF. The CAT AS ORF is flanked
by the 5 UTR-IGR and 3 UTR of the LCMV S RNA.
Plasmid pTMI-GFP was included to assess the efficiency of
transfection based on GFP expression, and to control for a
possible effect of FU or Rib on T7 RNA polymerase-
mediated expression of plasmid supplied LCMV MG RNA
and trans-acting factors NP and L. In all cases, the amount
of DNA used in the transfections was normalized to 2.7
g/M6 well by using pTMI plasmid. Transfections were
performed using Lipofectamine (Life Technologies). GFP
expression was assessed by epifluorescence microscopy be-
fore harvesting the transfected cells. Cells were resuspended
in 2 ml of phosphate buffered saline (PBS) and split in two
equal aliquots. One aliquot was resuspended in 50 l 0.25
M Tris–HCl pH 7.5, and cell lysates were prepared and
assayed for CAT activity (Lee et al., 2000). The other
aliquot was resuspended in lysis buffer (50 mM Tris–HCI
pH 8, 6.25 mM EDTA, 1% NP-40, 0.4% deoxycholate) and
used for analysis of protein expression by Western blot.
RT-PCR and nucleotide sequencing
RNA was isolated from preextinction populations of
passages in the presence of FU (P2) or Rib (P1), and
untreated controls (P5). RNA samples were subjected to
RT-PCR to amplify genomic regions corresponding to three
different LCMV genes: NP, GP and L. Reverse transcrip-
tion of RNA to cDNA was performed using Superscript II
RT, starting with 1 g of RNA and using random hexamers
as primers. Amplification of cDNA was performed using
Taq polymerase (Boehringer Mannheim) as specified by the
manufacture and the appropriate LCMV specific primers to
amplify coding regions comprising the following amino
acids of GP, NP, and L: 59 to 227 (GP), 190 to 360 (NP) and
2040 to 2210 (L). The sequence of oligonucleotides, prim-
ers, and specific PCR conditions used are available from the
authors upon request. RT-PCR products were fractionated
by agarose gel electrophoresis and fragments with the pre-
dicted sizes purified and cloned. DNA sequencing was done
with an ABI 373 automatic sequencer.
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